Protein Kinase Inhibitors: all 15,278 studies that test it

Page 117 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib for Treating Uterine LeiomyosarcomaWithdrawnNCT02378142Phase 2
• Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal CancerStatus unknownNCT02375581Phase 2
• Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR MutationsStatus unknownNCT02375022Phase 2
• A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
• A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar CholangiocarcinomaTerminatedNCT02374489Phase 2
• A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaTerminatedNCT02372227Phase 1
• Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisCompletedNCT02370706Phase 1
• A Study of LY2801653 in Healthy Participants Who Are Not Able to Have ChildrenCompletedNCT02370485Phase 1
• Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue SarcomaWithdrawnNCT02367651Phase 2
• Phase I Study of Oral BAY 1217389 in Combination With Intravenous PaclitaxelCompletedNCT02366949Phase 1
• A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Active, not recruitingNCT02365441Phase 2
• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent PlacementWithdrawnNCT02365415Phase 2
• Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed GlioblastomaCompletedNCT02364206Phase 1/2
• Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility StudyStatus unknownNCT02363361Phase 2
• Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyTerminatedNCT02362230Phase 2
• Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWithdrawnNCT02357732Phase 1
• A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
• Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
• Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
• A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT02354898Phase 1
• A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of EsophagusStatus unknownNCT02353936Phase 2
• Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerCompletedNCT02349867Phase 1
• Phase II Study of Pazopanib and Topotecan in Cervical CancerWithdrawnNCT02348398Phase 2
• Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract AdenocarcinomaCompletedNCT02346032Phase 2
• Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic GliomaStatus unknownNCT02345824Phase 1
• Phase I Dose Escalation of BAY1143572 in Subjects With Acute LeukemiaCompletedNCT02345382Phase 1
• C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal CancerWithdrawnNCT02344810Phase 1/2
• Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast CancerCompletedNCT02344550Phase 2
• Detect V / CHEVENDO (Chemo vs. Endo)Active, not recruitingNCT02344472Phase 3
• Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursCompletedNCT02343718Phase 1
• Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem MalignanciesWithdrawnNCT02343679Phase 2
• Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With LiposarcomaCompletedNCT02343172Phase 1
• Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHLCompletedNCT02342665Phase 1/2
• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)WithdrawnNCT02342600Phase 2
• Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced CancerCompletedNCT02342587Phase 2
• Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
• A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibCompletedNCT02340611Phase 2
• Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric BypassCompletedNCT02340247Phase 4
• Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal DialysisStatus unknownNCT02338635Phase 4
• Trial of Olaparib in Combination with AZD5363 (ComPAKT)CompletedNCT02338622Phase 1
• Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)TerminatedNCT02338570Phase 4
• Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior TrastuzumabCompletedNCT02338245Phase 2
• Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)Status unknownNCT02338011Phase 2/3
• SF1126 for Patients With Relapsed or Refractory NeuroblastomaTerminatedNCT02337309Phase 1
• Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic KeratosisCompletedNCT02337205Phase 1
• A Study of Famitinib in Patients With Gastrointestinal Stromal TumorStatus unknownNCT02336724Phase 2
• First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
• Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy SubjectsCompletedNCT02334501Phase 1
• Combination of Everolimus and Octreotide LAR in Aggressive Recurrent MeningiomasCompletedNCT02333565Phase 2
• A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast CancerCompletedNCT02333370Phase 1
• Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Status unknownNCT02332512Phase 3
• Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)CompletedNCT02332499Phase 2/3
• Sorafenib Drug Drug Interaction Study in Healthy Male SubjectsCompletedNCT02332031Phase 1
• Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02331498Phase 1/2
• Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCStatus unknownNCT02330367Phase 1/2
• Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompletedNCT02328963Phase 4
• A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal CarcinomaStatus unknownNCT02328261Phase 2
• Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional TherapiesCompletedNCT02326441Phase 1
• Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
• Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBTerminatedNCT02326285Phase 2/3
• Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC PatientsStatus unknownNCT02324803Phase 2
• A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE InhibitorsTerminatedNCT02322853Phase 2
• Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect StudyCompletedNCT02321644Phase 1
• Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingNCT02321501Phase 1
• A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)CompletedNCT02320409Phase 1
• Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric SurgeryStatus unknownNCT02319629Not applicable
• Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal TumorsCompletedNCT02319018Phase 1
• Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
• Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedNCT02316197Phase 1
• Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)CompletedNCT02315326Phase 1/2
• A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)CompletedNCT02314819Phase 3
• Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
• Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI DonorsStatus unknownNCT02314312Phase 3
• Everolimus trIal for Advanced prememopausaL Breast Cancer PatientsStatus unknownNCT02313051Phase 2
• Safety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsTerminatedNCT02313012Phase 1
• Ph Ib/BGJ398/Cervix and Other Solid TumorsWithdrawnNCT02312804Phase 1
• A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of PalbociclibCompletedNCT02311946Phase 1
• Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)Status unknownNCT02311205Phase 2
• Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2
• Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaCompletedNCT02309580Phase 1
• Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCompletedNCT02308553Phase 1/2
• Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard TherapyCompletedNCT02307500Phase 2
• A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell CancerWithdrawnNCT02307474Not applicable
• Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145CompletedNCT02307461Phase 1
• Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsCompletedNCT02307240Phase 1
• A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With EverolimusCompletedNCT02305810Phase 2
• Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic AlterationsActive, not recruitingNCT02304809Phase 2
• A Study of Galunisertib on the Immune System in Participants With CancerCompletedNCT02304419Phase 1
• Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
• Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural MesotheliomaCompletedNCT02303899Phase 2
• Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic SubjectCompletedNCT02303509Phase 1
• Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid TumoursCompletedNCT02303028Phase 1/2
• Study of Trametinib and Nab-paclitaxel in Patients With MelanomaWithdrawnNCT02300935Phase 1
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
• Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell CarcinomaWithdrawnNCT02298595Phase 1/2
• Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
• Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
• A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung CancerWithdrawnNCT02297425Phase 2
• Bioavailability Study of Sirolimus Tablets 2 mg Under Fed ConditionCompletedNCT02296762Phase 1

← Protein Kinase Inhibitors overview